哌嗪二酮治疗晚期或复发性子宫内膜癌的II期试验。一项妇科肿瘤学组研究。
Phase II trial of piperazinedione in the treatment of advanced or recurrent endometrial carcinoma. A Gynecologic Oncology Group Study.
作者信息
Thigpen J T, Blessing J A, Homesley H D, Petty W
出版信息
Am J Clin Oncol. 1986 Feb;9(1):21-3. doi: 10.1097/00000421-198602000-00006.
Twenty-three patients with advanced or recurrent endometrial carcinoma no longer amenable to control with surgery and/or radiotherapy were entered into study. Twenty-two actually received therapy with piperazinedione at a dose of 9 mg/m2 intravenously every 3 weeks. One partial responder was observed. Adverse effects were primarily manifested as myelosuppression, and were significant but tolerable. Due to the low order of activity observed, this drug is not recommended for further study in the treatment of endometrial carcinoma.
23例晚期或复发性子宫内膜癌患者，不再适合接受手术和/或放疗控制，进入本研究。22例患者实际接受了哌嗪二酮治疗，剂量为9mg/m²，每3周静脉注射一次。观察到1例部分缓解者。不良反应主要表现为骨髓抑制，程度显著但可耐受。由于观察到的活性较低，不建议该药物进一步用于子宫内膜癌治疗的研究。
Zotero 插件